PE20050357A1 - Composicion que comprende 5-[4-[2-(n-metil-n-(2-piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona - Google Patents

Composicion que comprende 5-[4-[2-(n-metil-n-(2-piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona

Info

Publication number
PE20050357A1
PE20050357A1 PE2004000771A PE2004000771A PE20050357A1 PE 20050357 A1 PE20050357 A1 PE 20050357A1 PE 2004000771 A PE2004000771 A PE 2004000771A PE 2004000771 A PE2004000771 A PE 2004000771A PE 20050357 A1 PE20050357 A1 PE 20050357A1
Authority
PE
Peru
Prior art keywords
etoxy
diona
pyridyl
benzyl
amino
Prior art date
Application number
PE2004000771A
Other languages
English (en)
Inventor
Peter John Coles
Donald Colin Mackenzie
Jr Paul Norman Mudd
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of PE20050357A1 publication Critical patent/PE20050357A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE (A) UN NUCLEO EROSIONABLE QUE INCLUYE 5-[4-[2-(N-METIL-N-(2-PIRIDIL)-AMINO)-ETOXI]-BENCIL]-TIAZOLIDINO-2,4-DIONA, O UNA SAL O SOLVATO DE ESTA Y UN AGENTE ANTIDIABETICO ADICIONAL COMO METFORMINA, Y, (B)UN NUCLEO QUE POSEE UN RECUBRIMIENTO ENTERICO E IMPERMEABLE CON UNA O MULTIPLES ABERTURAS QUE CONDUCEN A EL Y SE EROSIONA A PH DETERMINADO. TAMBIEN REFERIDO A UN METODO DE TRATAMIENTO Y/O PROFILAXIS DE DIABETES, ENTRE OTRAS
PE2004000771A 2003-08-11 2004-08-09 Composicion que comprende 5-[4-[2-(n-metil-n-(2-piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona PE20050357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition

Publications (1)

Publication Number Publication Date
PE20050357A1 true PE20050357A1 (es) 2005-06-01

Family

ID=27840010

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000771A PE20050357A1 (es) 2003-08-11 2004-08-09 Composicion que comprende 5-[4-[2-(n-metil-n-(2-piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona

Country Status (37)

Country Link
US (1) US20080206336A1 (es)
EP (1) EP1663191B1 (es)
JP (1) JP4714147B2 (es)
KR (1) KR20060071396A (es)
CN (2) CN1835741B (es)
AP (1) AP2006003489A0 (es)
AR (1) AR045230A1 (es)
AT (1) ATE455542T1 (es)
AU (1) AU2004262933B2 (es)
BR (1) BRPI0413419A (es)
CA (1) CA2534480A1 (es)
CY (1) CY1109923T1 (es)
DE (1) DE602004025257D1 (es)
DK (1) DK1663191T3 (es)
EA (2) EA011550B1 (es)
EC (1) ECSP066338A (es)
ES (1) ES2339554T3 (es)
GB (1) GB0318824D0 (es)
HK (1) HK1092051A1 (es)
HR (1) HRP20100160T1 (es)
IL (1) IL173177A0 (es)
IS (1) IS2745B (es)
MA (1) MA27996A1 (es)
MX (1) MXPA06001629A (es)
MY (1) MY151053A (es)
NO (1) NO20061161L (es)
NZ (1) NZ544632A (es)
OA (1) OA13233A (es)
PE (1) PE20050357A1 (es)
PL (1) PL1663191T3 (es)
PT (1) PT1663191E (es)
SG (1) SG165178A1 (es)
SI (1) SI1663191T1 (es)
TW (1) TW200517146A (es)
UA (1) UA82537C2 (es)
UY (1) UY28461A1 (es)
WO (1) WO2005013956A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
JP2011528666A (ja) * 2008-07-18 2011-11-24 バレアント プハルマセウトイカルス インターナショナル 放出調節製剤及びその使用方法
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
CA2804926C (en) * 2010-07-09 2019-01-08 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
CN105663130B (zh) * 2011-04-15 2019-08-09 江苏豪森药业集团有限公司 一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
EP1001014B1 (en) * 1998-11-10 2006-01-11 The Procter & Gamble Company Bleaching compositions
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DE69939485D1 (de) * 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
AU5745601A (en) * 2000-05-01 2001-11-12 Aeropharm Technology Inc A core formulation
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
EA200800966A1 (ru) 2009-04-28
AU2004262933A1 (en) 2005-02-17
NZ544632A (en) 2009-03-31
US20080206336A1 (en) 2008-08-28
IS8337A (is) 2006-03-02
EP1663191A1 (en) 2006-06-07
EA200600400A1 (ru) 2006-08-25
IL173177A0 (en) 2006-06-11
AR045230A1 (es) 2005-10-19
PL1663191T3 (pl) 2010-06-30
UY28461A1 (es) 2005-03-31
MY151053A (en) 2014-03-31
CA2534480A1 (en) 2005-02-17
UA82537C2 (uk) 2008-04-25
JP4714147B2 (ja) 2011-06-29
DK1663191T3 (da) 2010-04-26
MA27996A1 (fr) 2006-07-03
EP1663191B1 (en) 2010-01-20
DE602004025257D1 (de) 2010-03-11
NO20061161L (no) 2006-03-10
SG165178A1 (en) 2010-10-28
CN102397551A (zh) 2012-04-04
KR20060071396A (ko) 2006-06-26
AP2006003489A0 (en) 2006-02-28
HK1092051A1 (en) 2007-02-02
AU2004262933B2 (en) 2009-12-10
SI1663191T1 (sl) 2010-05-31
HRP20100160T1 (hr) 2010-05-31
WO2005013956A1 (en) 2005-02-17
MXPA06001629A (es) 2006-04-28
ES2339554T3 (es) 2010-05-21
ATE455542T1 (de) 2010-02-15
PT1663191E (pt) 2010-03-16
CY1109923T1 (el) 2014-09-10
EA011550B1 (ru) 2009-04-28
CN1835741B (zh) 2011-12-14
OA13233A (en) 2006-12-13
JP2007501830A (ja) 2007-02-01
BRPI0413419A (pt) 2006-10-10
GB0318824D0 (en) 2003-09-10
CN1835741A (zh) 2006-09-20
TW200517146A (en) 2005-06-01
IS2745B (is) 2011-08-15
ECSP066338A (es) 2006-07-28

Similar Documents

Publication Publication Date Title
ES2527833T3 (es) Combinaciones de principios activos nematicidas que comprenden fluopiram y otro principio activo
PE20050357A1 (es) Composicion que comprende 5-[4-[2-(n-metil-n-(2-piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
CL2012001337A1 (es) Uso de una combinacion farmacéutica que comprende un inhibidor de dpp-4 y opcionalmente un segundo y/o un tercer agente diabético seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, glp-1 e insulina, diferentes entre ellos, para el tratamiento de diabetes mellitus de tipo 2.
PA8556201A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
ES2526555T3 (es) Composición fungicida y método para controlar enfermedades de plantas
GT200500179A (es) Mezclas sinergistas de agentes de antranilamida para el control de plagas de invertebrados
PE20081752A1 (es) Sal de napadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2-(1h)-ona como agonista del receptor adrenergico b2
PE20070458A1 (es) Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
CL2007003193A1 (es) Metodo para evitar o reducir la vasoconstriccion a continuacion de la administracion de un portador de oxigeno vasoactivo, que comprende oxido nitrico gaseoso y otro agente activo; composicion farmaceutica que comprende un inhibidor de fosfodiesteras
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
PE20051051A1 (es) Compuestos de triazol como antagonistas de la vasopresina
ECSP056011A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
AR061070A1 (es) Preparacion oral que comprende pioglitazona
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
CL2007003272A1 (es) Compuestos derivados de pirazol y triazol sustituidos; y composicion farmaceutica, util para el tratamiento de una enfermedad proliferativa celular.
CO6341527A2 (es) Composiciones pesticidas
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
PE20090320A1 (es) Derivados de piperidina-amida
CL2007003451A1 (es) Composicion farmaceutica solida oral que comprende un principio activo y polivinilpirrolidona (pvp) entre 1,0-25%, cpaa entre 0,5-10%, el principio activo consiste en una sal hidrosoluble de metal alcalino, de metal alcalino-terreo, una sal de mezcla
PE20091410A1 (es) Asociacion entre un sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave

Legal Events

Date Code Title Description
FC Refusal